Who are AGB101's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): [18F]Florbetapir PET imaging, Florbetapir F 18 (18F-AV-45), Neuraceq (florbetaben 18F), PiB, Lecanemab SC, ABP 692.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/agb101.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

AGB101 — Competitive Intelligence Brief

AGB101 (AGB101) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Neurology.

phase 2 Monoclonal antibody Amyloid-beta Neurology Small molecule Live · refreshed every 30 min

Target snapshot

AGB101 (AGB101) — AgeneBio. AGB101 is a monoclonal antibody targeting amyloid-beta

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AGB101 TARGET	AGB101	AgeneBio	phase 2	Monoclonal antibody	Amyloid-beta
[18F]Florbetapir PET imaging	[18F]Florbetapir PET imaging	Institute for Neurodegenerative Disorders	marketed	PET imaging agent	Amyloid-beta (Aβ) fibrils
Florbetapir F 18 (18F-AV-45)	Florbetapir F 18 (18F-AV-45)	University of California, San Francisco	marketed	PET imaging agent	Amyloid-beta (Aβ) plaques
Neuraceq (florbetaben 18F)	Neuraceq (florbetaben 18F)	Piramal Imaging Limited	marketed	PET imaging agent	Amyloid-beta plaques
PiB	PiB	NYU Langone Health	marketed	PET imaging tracer	Amyloid-beta (Aβ) fibrils
Lecanemab SC	Lecanemab SC	Eisai Inc.	phase 3	Monoclonal antibody (anti-amyloid-beta)	Amyloid-beta protofibrils
ABP 692	ABP 692	Amgen	phase 3	Monoclonal antibody (anti-amyloid-beta)	Amyloid-beta protofibrils

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

Pfizer · 7 drugs in this class
argenx · 7 drugs in this class
Johnson & Johnson · 2 drugs in this class
German CLL Study Group · 2 drugs in this class
Amgen · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Brii Biosciences Limited · 2 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Biotest · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AGB101 — Competitive Intelligence Brief. https://druglandscape.com/ci/agb101. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab